Weight-loss drug Wegovy will go on sale in Korea on Tuesday, with the much-anticipated injectable drug available for order through Zeullig Pharma Korea.

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is typically more affordable than Wegovy. At the time of publishing, the list price for Ozempic was $968.52 per month, whereas the list price for Wegovy was $1,349.02 per month. List prices are the price set by the manufacturer.

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, thigh or stomach. They work as an appetite suppressant by mimicking a hormone called glucagon-like peptide-1 (GLP-1).

This article delves into the pros and cons of these drugs, addressing potential side effects (including the rare ones).

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.

A sign at a pharmacy in Jongno District, central Seoul, says that Wegovy, a weight-loss drug, is available for sale on Thursday.